The EPS beat and clinical milestone (enrollment completion) are positive, but the stock is binary on NDA acceptance and eventual approval. Monitor for NDA submission in Q1 2027 and any FDA feedback; cash runway through Q2 2027 provides a buffer but raises financing risk if approval is delayed.
Price Chart
Executive Summary
PMV Pharma reported Q2 2026 EPS of -$0.34, beating the -$0.38 consensus by 10.5%, and completed enrollment for the primary analysis in the Phase 2 PYNNACLE trial of rezatapopt in platinum-resistant/refractory ovarian cancer. The company plans to submit an NDA for accelerated approval in Q1 2027, with $79.4M cash providing runway through Q2 2027.
Key Financial Metrics
Key Facts
- EPS -$0.34 vs consensus -$0.38 (10.5% beat)
- Net loss $18.1M vs $21.2M in Q2 2025 (narrowed 14.6%)
- Cash, equivalents, and marketable securities $79.4M as of June 30, 2026
- Enrollment completed for Phase 2 PYNNACLE monotherapy primary analysis in platinum-resistant/refractory ovarian cancer
- NDA submission for rezatapopt planned in Q1 2027
- Cash runway expected through Q2 2027
Financial Impact
EPS beat of $0.04 per share (10.5%) on a pre-revenue base; cash burn of $34.3M in H1 2026 vs $36.6M in H1 2025
Risk Factors
- NDA submission and accelerated approval are not guaranteed; clinical data may not support filing
- Cash runway only through Q2 2027; additional financing likely needed before potential approval
- Pre-revenue biotech with binary catalyst; stock has historically reacted negatively to prior filings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345278 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $1.78 | awaiting T+20 | — | $1.13 (−36.52%) |
Aug 31, 2026 7w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | 8-K | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▼ −29.46% | ▼ −29.14% | $1.13 (+12.40%) |
Aug 31, 2026 8w ago | Press Release | $1.29 $1.67 | ▲ +29.46% | ▲ +29.14% | $1.13 (−12.40%) |
Aug 14, 2026 10w ago | 8-K | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
Aug 14, 2026 10w ago | Press Release | $1.26 $1.46 | ▲ +15.87% | ▲ +17.86% | $1.13 (−10.32%) |
May 12, 2026 23w ago | 8-K | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
May 12, 2026 23w ago | Press Release | $1.42 $1.06 | ▼ −25.35% | ▼ −23.62% | $1.13 (−20.42%) |
Apr 22, 2026 26w ago | DEFA14A | $1.48 $1.31 | ▼ −11.49% | ▼ −14.65% | $1.13 (−23.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers